Fiztasovimab（Cat No.:I042101）is an investigational monoclonal antibody targeting CD47, a protein often overexpressed on cancer cells. CD47 functions as a “don’t eat me” signal, preventing the immune system’s macrophages from engulfing and destroying cancer cells. By blocking CD47, fiztasovimab aims to enhance the immune system’s ability to recognize and eliminate tumor cells. It is being studied in clinical trials for various cancers, including solid tumors and hematologic malignancies. The antibody is being tested for its potential to improve patient outcomes when combined with other immunotherapies or treatments, such as chemotherapy.
